Compass Therapeutics Inc(CMPX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:40 PM ET (Korea 10/31 07:40)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.4 | Insider Own | 28.51% | Shs Outstand | 180.1M | Perf Week | 3.35% |
| Market Cap | 0.14B | Forward P/E | - | EPS next Y | -12.62% | Insider Trans | 0.04% | Shs Float | 128.7M | Perf Month | -12.72% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -0.13 | Inst Own | 73.16% | Short Float | 32.5% | Perf Quarter | -58.28% |
| Income | -0.07B | P/S | - | EPS this Y | -18.1% | Inst Trans | -0.21% | Short Ratio | 9.88 | Perf Half Y | -59.87% |
| Sales | 0.00B | P/B | 0.85 | EPS next 5Y | -0.43% | ROA | -47.87% | Short Interest | 41.84M | Perf YTD | -85.35% |
| Book/sh | 0.92 | P/C | 0.79 | EPS past 3/5Y | -4.18% 5.72% | ROE | -56.66% | 52W High | -88.57% ($6.88) | Perf Year | -78.86% |
| Cash/sh | 1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -42.2% | 52W Low | 7.74% ($0.73) | Perf 3Y | -55.56% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 10.44% | Gross Margin | - | Volatility(W/M) | 7.24% 7.97% | Perf 5Y | -73.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.22 | EPS Q/Q | 6.33% | Profit Margin | - | RSI (14) | 27.28 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.22 | Sales Q/Q | - | SMA20 | -8.7% ($0.87) | Beta | 1.01 | Target Price | $5.5 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/6 | SMA50 | -46.22% ($1.47) | Rel Volume | 0.69 | Prev Close | $0.76 |
| Employees | 39 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | -17.43% 100% | SMA200 | -75.35% ($3.2) | Avg Volume(3M) | 4.24M | Price | $0.79 |
| IPO | 2021/4/5 | Option/Short | Yes/Yes | Trades | 5589 | Volume | 2,918,281 | Change | 4.01% |
🧬 Compass Therapeutics (ticker: CMPX) is a US clinical-stage biotech company developing antibody-based anticancer therapies. Its lead asset is tovesmab (codenamed CTX009), a bispecific antibody that simultaneously targets two key drivers of tumor angiogenesis — Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). The company is currently running a late-stage clinical trial of tovesmab in biliary tract cancer. Built around its proprietary antibody platform that blocks tumor blood vessel formation, Compass Therapeutics is also expanding its pipeline with additional programs.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
CMPX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -18.1% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -74.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
32.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #330 of 597 in the industry
Based on market cap of $142M.
MSLE#329 Satellos Bioscience Inc $142M PER - CMPX#330 Compass Therapeutics Inc $142M PER - 
MENS#331 Jyong Biotech Ltd $140M PER - 
NBP#332 NovaBridge Biosciences ADR $139M PER - 
MOLN#333 Molecular Partners AG ADR $137M PER - 
FAQ
What kind of company is CMPX?
CMPX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CMPX?
The market cap of CMPX is approximately $142M, ranking 4,260 within its sector.
What is the 52-week high and low for CMPX?
CMPX has recorded a 52-week high of $6.88 and a low of $0.73.
